Finding new ways to treat childhood cancers
Official title: Targeting Pediatric Cancer Vulnerabilities
Funded at Dana-Farber Cancer Inst · NIH-10931723 · Data updated 2026-11-12
This study is exploring new ways to treat kids with acute myeloid leukemia (AML) by using cutting-edge techniques to find better and safer medicines, so young patients can have more effective treatments than the usual chemotherapy and radiation.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2030 |
| Funding year | 2024 |
| Award (this year) | $1,012,869 |
| NIH project number | 5R35CA283977-02 |
| Project ID | NIH-10931723 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include children diagnosed with acute myeloid leukemia or other pediatric cancers who are currently facing limited treatment options.
✕Less likely to help
Patients with adult cancers or those whose conditions do not involve the specific vulnerabilities being targeted in this research may not benefit.
What this research studies
This research investigates innovative approaches to target the unique vulnerabilities of pediatric cancers, particularly acute myeloid leukemia (AML). The project aims to overcome existing treatment limitations by utilizing advanced techniques like CRISPR to identify and validate new drug targets. By focusing on the molecular characteristics of childhood cancers, the research seeks to develop more effective and less harmful therapies compared to traditional methods such as chemotherapy and radiation. The principal investigator, a pediatric oncologist, is committed to advancing precision medicine for young patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for children with cancer, significantly improving their chances of survival and quality of life.
How similar studies have gone: While there has been significant progress in adult cancer therapies, this approach to pediatric cancers is relatively novel and aims to address specific challenges that have not been extensively explored.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Stegmaier, Kimberly — Dana-Farber Cancer Inst
- Study coordinator: Stegmaier, Kimberly
Related research
Other NIH-funded projects on the same topics.
-
Deep profiling of how fusion-driven pediatric cancers spread, using single-cell protein tools
Researchers will develop fast, highly capable single-cell protein measurements to understand how certain pediatric cancers, like Ewing sarcoma, spread and evade the immune system.
-
Radiation therapy and data science to help kids with cancer
Scientists from two top cancer centers are teaming up to make radiation for pediatric cancers more powerful and precise, using data science to guide treatment for children with two tough tumors.
-
Targeting childhood cancer vulnerabilities with CRISPR-based screens
A pediatric cancer research project uses CRISPR screens to find new, druggable weaknesses in childhood leukemias to guide safer, targeted therapies.
-
Genetic links between birth anomalies and childhood cancer in kids and young people
This grant tests how inherited birth defects and genetic factors may increase the risk of cancer in children and teens, using real-world birth and cancer data to understand shared genetics.
-
A living-cell detector for ALT-related biomarkers in pediatric bone cancers
A new, cell-based tool will help scientists see ALT activity in cancer cells from pediatric tumors, potentially guiding future therapies.
-
Using children's tumor protein and genetic data to find better treatments
This project analyzes tumor DNA, RNA, proteins, and protein modifications to find potential treatment targets for children with brain tumors and leukemias.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.